Latest posts tagged with #ExpeditionRNA on Bluesky
Our CEO Michael Gilman and CBO James Mutamba will be in San Francisco for the JPM conference next week, Jan 12-15. Looking forward to great meetings and connections, and we hope to see you there!
#ExpeditionRNA #JPM2026
We’re welcoming 2026 with renewed focus. Our team remains committed to advancing RNA-targeted medicines and continuing the important work ahead. Wishing all a bright, healthy start to the new year!
#ExpeditionRNA
Our team gathered for a casual holiday get-together, sharing food, laughter, and a chance to appreciate the incredible people behind our mission. Our gingerbread house creations were truly inspired and festive! Grateful for this team today and every day.
#ExpeditionRNA
Our CEO Michael Gilman and CBO James Mutamba will be in San Francisco for the JPM conference next month, Jan 12-15, 2026. Looking forward to great meetings and connections!
#ExpeditionRNA #JPM2026
This week we slow down and express gratitude for our phenomenal team and their commitment to each other, our core values, and our mission.
Happy Thanksgiving to all.
#ExpeditionRNA
Today, we join the world in recognizing UNESCO World #ScienceDay. This year’s theme: ‘Trust, Transformation, and Tomorrow: The Science We Need for 2050’ makes us excited about our mission to change the way challenging diseases are treated. #ExpeditionRNA
Learn more: www.unesco.org/en/days/scie...
Monday at the HBM Biopharma Summit 2025 in Zurich, our Chief Business Officer James Mutamba will give a corporate presentation and Arrakis overview.
#ExpeditionRNA
Our CEO Michael Gilman will share his experiences and discuss what it takes to scale innovation for lasting impact during a fireside chat today at the BioPort Atlantic 2025 conference in Halifax.
#ExpeditionRNA
To celebrate #RNADay at Arrakis, we constructed our own ‘Arrakis RNA’ made with RNA codons that translate into amino acids that represent us, whether it be one of our initials or our favorite letter, and what we can create as a team!
#ExpeditionRNA #WeAreArrakeen
Happy #RNADay! Today we celebrate all things RNA, the foundation of our mission to create rSMs (RNA-targeted small molecules) that act directly on RNA to treat disease.
#ExpeditionRNA
It’s #ImmigrantHeritageMonth, and we are proud of our backgrounds and the cultural diversity on #ExpeditionRNA.
We recognize the important role that immigrants play in our success at Arrakis and our communities. #DareToBeArrakeen
Today our CSO Jennifer Petter joins the hosts of the Drug Hunter Flash Talk, an ongoing series of talks about drug discovery, for a discussion of drugging RNA with small molecules.
#ExpeditionRNA
Listen here:
drughunter.com/flashtalks?u...
We’re honored to be named winner of the #CitelineAwards 2025 for Most Successful Early Phase Research (Preclinical & Phase I) at last night’s event! Thank you to Citeline and to every member of our team for their hard work and dedication. Congratulations to all nominees and winners! #ExpeditionRNA
We’re looking forward to tonight’s #CitelineAwards 2025 ceremony, as a finalist for Most Successful Early Phase Research (Preclinical & Phase I). #ExpeditionRNA
At the RNA-AI Conference 2025 in Ascona, Switzerland today, Luis, Associate Director of Computational Biology, will present on our proprietary platform to develop RNA-targeted small molecule (rSMs) medicines. #ExpeditionRNA
www.rna-ai.org
Arrakis is at the 2025 MDF International Conference. Proud to sponsor the Pharma Day pre-event hosted by Euro-DyMA where Sarah, Director of Discovery Biology, presented. She presents at the main conference Sat on our proprietary platform for RNA-target small molecule (rSMs) medicines. #ExpeditionRNA
We’re honored to announce that Arrakis has been selected as a #CitelineAwards 2025 finalist for Most Successful Early Phase Research (Preclinical & Ph I)! In 2 weeks, we’ll be gathering with the finalists & industry leaders at the awards celebration. #ExpeditionRNA
www.citeline.com/en/awards/ci...
Today, Elena, Director of Structural Biology, presents at the Drug Discovery Chemistry Conference, discussing our structure-enabled approach to developing RNA-targeted small molecule (rSMs) medicines.
#ExpeditionRNA
At the Applied Pharmaceutical Chemistry conference in Boston today, Karthik, Director of Medicinal Chemistry, presented on our proprietary platform to develop RNA-targeted small molecule (rSMs) medicines.
#ExpeditionRNA
Today at the 2nd Biophysics for Drug Discovery Summit in Boston, Griffin Schroeder, Scientist II, will present on our work to target RNA for new small molecule (rSM) medicines. #ExpeditionRNA #ArrakeensInAction
In an oral presentation at the #MDAconference today in Dallas, Domi Stickens, PhD, our VP of Discovery and Translational Sciences, will present preclinical data for our RNA-targeted small molecule (rSM) drug program for myotonic dystrophy type 1 (DM1), a form of muscular dystrophy. #ExpeditionRNA
In an oral presentation at the MDA Clinical & Scientific Conference next week, we will present preclinical data for our lead, rationally designed, RNA-targeted small molecule drug program for treatment of myotonic dystrophy type 1 (DM1). #MDAconference #ExpeditionRNA
arrakistx.com/press-releas...
Today, Kathleen McGinness, PhD, our VP of Platform Biology, will present on our work to target RNA for new small molecule (rSM) medicines at the CHDI 20th Annual Huntington’s Disease Therapeutics Conference in Palm Springs, CA. #ExpeditionRNA #ArrakeensInAction
Our CEO Michael Gilman @gilman.bsky.social, CSO Jennifer Petter and CBO James Mutamba will be in San Francisco for the JPM conference next week, Jan 13-16. Looking forward to great meetings and connections! #ExpeditionRNA #JPM2025
We’re welcoming 2025 at Arrakis, committed to pioneering a new class of genetic medicines: RNA-targeted small molecules (rSMs). We’re looking ahead to new milestones and to building relationships with new partners this year. #ExpeditionRNA
arrakistx.com
Arrakeens gathered for an end-of-year party to celebrate the accomplishments and hard work of this year. We’re looking forward to more milestones in 2025. #ExpeditionRNA
A capstone to 2024 was our presentation of preclinical data this month for the first RNA-targeted small molecule (rSM) drug program we’re advancing to treat DM1, a form of muscular dystrophy. As we enter 2025, we’ve reached an inflection point and we can’t stop now. #ExpeditionRNA
arrakistx.com
Two Arrakeens share their expertise on RNA-targeted therapeutics at the RNA-targeted Drug Discovery Summit in Boston this week. Domi Stickens PhD, VP Discovery & Translational Sciences, presents and serves as a panelist, and Founder & CSO Jennifer Petter PhD is on a different panel. #ExpeditionRNA
Data we present today at the #CellSymposia for our first RNA-targeted small molecule (rSM) drug program supports additional product development with our multi-modality rSM drug platform. We aim to broaden the reach of genetic medicine with oral drugs. #ExpeditionRNA
arrakistx.com/press-releas...
Arrakis Founder and CSO Jennifer Petter presents the first data for our lead drug program using our proprietary platform to develop RNA-targeted small molecule (rSMs) medicines today at the #CellSymposia. #ExpeditionRNA
arrakistx.com/wp-content/u...
